<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Guideline for the diagnosis of drug hypersensitivity reactions S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2019-01-01">January 1, 2019</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Knut</forename><surname>Brockow</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernhard</forename><surname>Przybilla</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Aberer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Randolf</forename><surname>Brehler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Heinrich</forename><surname>Dickel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Fuchs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Thilo</forename><surname>Jakob</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Lange</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Pfützner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maja</forename><surname>Mockenhaupt</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hagen</forename><surname>Ott</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Oliver</forename><surname>Pfaar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><surname>Ring</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bernhardt</forename><surname>Sachs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Helmut</forename><surname>Sitter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Axel</forename><surname>Trautmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Regina</forename><surname>Treudler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bettina</forename><surname>Wedi</surname></persName>
						</author>
						<author>
							<persName><roleName>MARGITTA WORM 19</roleName><forename type="first">Gerda</forename><surname>Wurpts</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Torsten</forename><surname>Zuberbier</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><forename type="middle">F</forename><surname>Merk</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Dermatology and Allergology Biederstein</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Allergology</orgName>
								<orgName type="department" key="dep3">Allergy Center</orgName>
								<orgName type="institution">Technical Technische University Universität of MünchenMunich</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Ludwig Maximilian University of Munich</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Allergology</orgName>
								<orgName type="institution">Medical University of Graz</orgName>
								<address>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University Hospital Basle</orgName>
								<address>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution">Münster University Hospital</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution" key="instit1">St. Josef Hospital</orgName>
								<orgName type="institution" key="instit2">Ruhr University Bochum</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Dermatology and Venereology</orgName>
								<orgName type="institution">Göttingen University Hospital</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">Freiburg University Hospital</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">Marien Hospital Bonn</orgName>
								<address>
									<settlement>Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<orgName type="institution">Gießen and Marburg University Hospital</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">German Center for the Documentation of Severe Skin Reactions</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Venereology</orgName>
								<orgName type="institution">Freiburg University Hospital</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Children&apos;s and Adolescents&apos; Hospital &quot;Auf der Bult</orgName>
								<orgName type="institution">ENT at Mannheim University Hospital</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Center for Rhinology and Allergology</orgName>
								<address>
									<settlement>Wiesbaden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Federal Institute for Drugs and Medicinal Products</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">Institute of Theoretical Surgery</orgName>
								<orgName type="institution">Philipps University</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<orgName type="institution" key="instit1">Mainfranken Allergy</orgName>
								<orgName type="institution" key="instit2">Würzburg University Hospital</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution">Leipzig University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution">Hannover Medical University</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Department of Dermatology, Venereology and Allergology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<orgName type="institution">RTWH</orgName>
								<address>
									<settlement>Aachen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Guideline for the diagnosis of drug hypersensitivity reactions S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2019-01-01">January 1, 2019</date>
						</imprint>
					</monogr>
					<idno type="MD5">AE7DA44AA8EDB15E18E126CCC064D6E9</idno>
					<idno type="DOI">10.1007/s40629-015-0052-6</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>drug hypersensitivitydiagnosis -skin test -in vitro test -provocation test</keywords>
			</textClass>
			<abstract xml:lang="nl">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Development stage S2K</head><p><s>AWMF Guidelines register number 061-021</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Whilst type-A adverse drug reactions (ADR) are caused by known pharmacological or toxic reactions, hypersensitivity drug reactions are caused by individual predisposing factors in the patient and are essentially unpredictable (type-B reactions) <ref type="bibr" target="#b0">[1]</ref>.</s><s>Drug allergy is distinct from a non-immunological drug hypersensitivity reaction (Tab. 1)</s><s>.</s></p><p><s>All cases of suspected hypersensitivity reactions associated with the use of drugs in any age group should undergo diagnostic investigation with the aim of identifying the trigger and possibly the underlying pathomechanism, assessing the patient's risk for further reactions, and advising the patient accordingly on this risk <ref type="bibr" target="#b1">[2]</ref>.</s><s>Dispensing with a diagnostic work-up can result in severe reactions on renewed exposure on the one hand, and to unjusti ed restrictions in terms of treatment options on the other.</s></p><p><s>e DGAKI and the DDG assigned the working group Arzneimittelallergie ("drug allergy") with the task of updating the current version of the guideline <ref type="bibr" target="#b0">[1]</ref>.</s><s>Following constitutive meetings on 11 October 2012 and 5 September 2013, K. Brockow, B. Przybilla, and H. Merk compiled a dra version of the new guideline by updating and revising the existing guideline <ref type="bibr" target="#b1">[2]</ref>.</s><s>Together with experts from other specialist societies and institutions largely involved in the treatment of patients with drug hypersensitivity reactions, recommendations were developed based on literature searches, an assessment of participants' experiences, and theoretical considerations.</s><s>At a consensus conference held on 15 April 2014, each recommendation was discussed and agreed on in a structured consensus-nding process under neutral moderation in order to solve open decision-making problems and to provide a nal assessment of the recommendations.</s></p><p><s>is guideline is addressed to all physicians, as well as other professionals working in the medical eld, involved in the diagnosis of and counseling on drug hypersensitivity reactions in patients of all age groups.</s><s>e general principles of clarifying drug hypersensitivity reactions are presented.</s><s>It is beyond the scope of this guideline to provide details on diagnostic methods or speci c procedures in the case of hypersensitivity reactions to individual drugs or drug groups, or on rare diseases induced by drug hypersensitivity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>De nition and classi cation</head><p><s>De nitions for the classi cation of ADR are given in Tab. 1 <ref type="bibr" target="#b0">[1]</ref>.</s><s>Diagnostic allergy tests are only useful in allergic or non-allergic hypersensitivity reactions, not, however, in pharmacological or toxic ADR.</s></p><p><s>Clinical classi cation on the basis of morphology, chronology, and time course is helpful for further diagnostic planning and permits the di erentiation of hypersensitivity reactions based on the time course (Tab.</s><s>2) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b2">3]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic methods</head><p><s>Investigations should be performed by an experienced allergist or at a specialized allergy center.</s><s>Knowledge of drugs that frequently elicit speci c hypersensitivity reactions is essential for diagnostic planning in order to be able to assess the likelihood with which a drug has caused a reaction.</s><s>Patient history as well as skin, in vitro, and provocation tests are used to identify the trigger.</s><s>A precise description and classi cation of the original reaction is of utmost importance.</s><s>Any diagnostic work-up should take into consideration the particular features of the individual case as well as the diagnostic options available (Fig. <ref type="figure" target="#fig_1">1</ref>) <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>Every e ort should be made to perform diagnostic allergy testing within 4 weeks-6 months a er the resolution of symptoms.</s><s>ere is evidence that successful detection of hypersensitivity several years a er the reaction is less frequent <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>Diagnostic testing for allergy in patients with no previous history of drug hypersensitivity ("prophetic testing") is not bene cial <ref type="bibr" target="#b6">[7]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient history and ndings clinical manifestation</head><p><s>e diagnostic success rate is higher in patients presenting during the acute phase of a reaction, since it is possible at that point to establish di erential diagnoses, classify clinical manifestations, and reliably interpret the course of symptoms in relation to drug use.</s><s>Creating a timeline diagram is recommended in cases where multiple drugs are taken.</s><s>Typical time intervals between rst drug intake and symptom onset are shown in Tab. 3.</s><s>Although information provided by the patient, as well as all available medical records relating to the reaction (e. g., discharge letter, medical chart, anesthetic chart) need to be consulted, these are sometimes unreliable.</s><s>A standardized questionnaire to collect relevant information is available <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>A test plan is formulated on the basis of all available information.</s></p><p><s>To this end, the following information should be documented: A. Clinical manifestation: -Documentation of clinical manifestations and/or organ systems involved, e. g., skin, respiratory</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tab. 1: De nitions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse drug reaction (ADR)</head><p><s>A noxious and unintended reaction that occurs alongside the intended principal effect of a drug, for which a causal relationship between the use of the drug and the adverse reaction is suspected</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse drug reaction (ADR)</head><p><s>ADRs can be both type A (pharmacological/toxic) and type B (hypersensitivity)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Skin tests</head><p><s>Skin tests are carried out in the context of hypersensitivity reactions involving symptoms consistent with allergy in order to determine a sensitization <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>As yet, there is no uniform standard for skin testing with drugs.</s><s>e European Network on Drug Allergy (ENDA) methods, which are currently being investigated in studies, are recommended <ref type="bibr" target="#b10">[11]</ref>.</s><s>In cases where provocation tests are not possible, e. g., as with muscle relaxants, skin testing plays a particularly important role in the diagnosis of allergy <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s></p><p><s>However, diagnostically useful skin test reactions occur only in some patients with hypersensitivity reactions.</s><s>Test substances in high concentrations can cause reactions even in healthy individuals.</s><s>It is  examples are given in Tab. 4 <ref type="bibr" target="#b13">[14]</ref>.</s><s>Where appropriate, natural rubber latex allergy should be excluded.</s></p><p><s>In extremely rare cases, skin testing with the trigger of a hypersensitivity reaction can cause systemic, occasionally life-threatening reactions.</s><s>e physician performing the skin test, as well as nursing sta must be prepared to deal with potential emergency situations <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17]</ref>.</s></p><p><s>De novo sensitization as a result of skin testing is possible, whereby this risk depends on the substance tested, its concentration, and the test method used.</s><s>erefore, intradermal tests and patch tests should only be performed with the drug suspected of triggering a reaction or relevant alternatives.</s></p><p><s>e indication for skin testing with non-standardized substances must be established according to particularly strict criteria.</s><s>Tests with incremental increases in the test substance concentration (threshold tests, e. g., 1 : 1000, 1 : 100, 1 : 10) can reduce the risk of severe allergic reactions during cutaneous testing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tab. 3: Typical time intervals between initial drug use and rst onset of symptoms</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro investigations</head><p><s>Particularly in the case of negative skin tests or severe life-threatening reactions, laboratory investigations can be helpful, most notably when provocation testing is not possible or where the skin test itself poses a risk, as in anaphylactic reactions to β-lactam antibiotics, for instance <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro diagnosis with drugs</head><p><s>Tests to measure speci c immunoglobulin E (IgE) antibodies to various drugs are available (Tab. 5).</s></p><p><s>Although cellular tests are sometimes helpful, they are only available at a limited number of centers and can cause problems in early childhood due to the large volumes of blood required <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>.</s></p><formula xml:id="formula_0">-</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Provocation tests</head><p><s>Provocation tests are indicated when the drug triggering hypersensitivity cannot be identi ed with su cient reliability on the basis of history, skin testing, and in vitro investigations and when the benet of information obtained from prvovocation testing outweighs the risks <ref type="bibr" target="#b21">[22]</ref>. is is o en the case.</s><s>Particularly in the case of suspected reactions to substances in drug groups that are essential or that cannot be permanently avoided (e. g., analgesics, antibiotics, local anesthetics), provocation tests also serve to identify tolerated drugs (alternative preparations in the case of possible drug cross-reactivity).</s><s>Drug provocation testing is indicated for the purposes of <ref type="bibr" target="#b21">[22]</ref>: -Excluding hypersensitivity when the history is unclear -Con rming the diagnosis when the history is suggestive but includes negative, unconvincing, or unavailable results from other diagnostic tests -Excluding cross-reactivity of related drugs e patient should be informed about the goal of diagnostic testing, the risks involved, the alternatives, as well as the test procedure, including the use of placebo.</s><s>Informed consent should be given in writing.</s></p><p><s>Medical supervision during the follow-up period, with the possibility of providing prompt intensive medical care if required, should be maintained for as long as severe reactions (e. g., anaphylaxis) can be expected.</s><s>For this reason, provocation tests likely to cause systemic reactions should be performed in an in-patient setting equipped to provide immediate emergency care (experienced medical and nursing sta , appropriate drugs and technical equipment).</s><s>Determining the procedure of drug provocation testing should always remain a case-by-case medical decision that takes numerous individual factors into consideration (e. g., type of drug, estimated likelihood of a reaction, expected severity of the reaction, patient expectations/anxiety).</s></p><p><s>e basic principle of provocation testing is to administer substances in the form in which they caused hypersensitivity reactions in the past.</s><s>Oral administration can be attempted with some substances, even though a di erent mode of administration was originally used (e.</s><s>g., i.m., i. v., rectal).</s><s>In some forms of reaction a local test at the reaction site in the sense of a "localized provocation test" is possible (e.</s><s>g., in xed drug eruptions with patch testing in loco).</s><s>As a basic rule, in-patient provocation tests should be performed in a placebo-controlled manner, since a large number of reactions are also seen with placebo tests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Test material</head><p><s>-Drugs, active ingredients, excipients -Test materials should be prepared in a form suited to single-/double-blind and fractionated administration Note: When investigating reactions to some drugs (e. g., non-steroidal anti-in ammatory drugs [NSAIDs]), it is advisable to also test alternative substances or preparations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment</head><p><s>-Provocation test results should be assessed preferably on the basis of objective parameters; nevertheless, subjective symptoms should also be recorded.</s><s>-Symptoms, as well as the evolution of a reaction over time, should be documented and, where possible, quantitative parameters measured (e. g., blood pressure, respiratory parameters, serum tryptase levels).</s><s>-In the case of drug reactions, further tests should be performed with active ingredients and excipients, where available -If a preparation of the suspected active substance as produced by a center's own pharmacy dispensary fails to induce a reaction, provocation should then be performed with the drug preparation used in the patient history.</s><s>-In the case of a reaction to placebo, perform reverse placebo provocation tests where appropriate (Tab.</s><s>6) Note: A negative provocation test does not reliably exclude hypersensitivity.</s><s>In particular, e ects exerted by the disease originally treated (e. g., viral infections), drug interactions, or a reduction in sensitivity over time can be responsible for false-negative results.</s><s>e negative predictive value of negative provocation testing to various drugs is &gt; 95 % in most cases, and the severity of the rare reactions seen under renewed re-exposure despite tolerance in provocation tests was mostly mild <ref type="bibr" target="#b23">[24,</ref><ref type="bibr">25]</ref>.</s></p><p><s>A reduction in the degree of sensitivity over time can be expected with allergic reactions that lie far in the past.</s><s>In such cases, although a provocation test may be negative, it may have a "booster" e ect.</s></p><p><s>erefore, in the case of a long interval between a reaction and testing, re-provocation testing a er 4-6 weeks may be considered.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Contraindications</head><p><s>e following contraindications exist for tests with suspected culprit drugs, as well as for tests with alternative preparations where cross-reactivity is assumed.</s><s>In speci c cases (e. g., suspected reactions to excipients), provocation testing may be justi ed, despite contraindications, in order to identify an active substance urgently required for treatment purposes.</s><s>An individual risk-bene t assessment is essential in all cases.</s></p><p><s>-Pregnancy and breastfeeding -Hypersensitivity reactions that may be beyond medical control (e. g., uncontrolled asthma, agranulocytosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, vasculitis, hepatopathy).</s><s>-Diseases or the use of drugs that carry an increased risk despite essentially controllable reactions (e. g., drugs contraindicated in anaphylaxis: severe cardiovascular disease, severe asthma, β-blocker use).</s><s>-Inadequate compliance, lack of understanding of the procedure on the part of the patient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overall assessment</head><p><s>e nal assessment of ndings needs to be made by taking not only results from skin, in vitro, and provocations tests but also, more particularly, the history of the clinical reaction into consideration.</s><s>Although drug hypersensitivity cannot be reliably ruled out even by applying all available test methods, they do makeenable better risk assessment easier.</s></p><p><s>e result of the overall assessment is discussed with the patient and documented.</s><s>Ideally, an allergy passport is issued, representing a medical document.</s></p><p><s>is provides information on the reaction type and substances/preparations not tolerated, along with information on possible cross-reactivities.</s><s>Possible (tested) alternative substances/preparations, as well as the maximum single and cumulative dose, should be stated (e.g., "paracetamol tolerated up to a single dose of 500 mg [cumulative 800 mg] in oral provocation").</s><s>Mention should also be made of the fact</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>-</head><label></label><figDesc><div><p><s>a) Immediate-type symptoms: e. g., flushing, urticaria, angioedema, bronchospasm, anaphylaxis b) Delayed-type symptoms: maculopapular drug eruptions, acute generalised exanthematic pustulosis (AGEP), severe cutaneous adverse reactions: Stevens-Johnson-Synrom (SJS), toxische epidermale Nekrolyse (TEN), "drug reaction with eosinophilia and systemic symptoms" (DRESS) c) Specific symptoms: e. g., hepatitis, cytopenias, autoimmune diseases (e.g., lupus erythematosus, Ig-A dermatosis) 3. Pathomechanisms a) Immunological hypersensitivity reaction: immediatetype (type I according to Coombs and Gell, mostly IgE-mediated): typical manifestation, immediate-type symptoms Reaction time: 0-6 h (in rare cases, up to 12 h) b) Non-immunological hypersensitivity reaction: typical manifestation, immediate-type symptoms Reaction time: 0-6 h (in rare cases, up to 12 h) c) Immunological hypersensitivity reaction: delayed-type (type IV according to Coombs and Gell, T cell-mediated): typical manifestation, delayed-type symptoms Reaction time: 24-72 h (in rare cases, after 6 h) d) Other immunological hypersensitivity reactions (type II, type III according to Coombs and Gell, IgG-, IgA, or IgM-mediated): cytopenias, serum sickness, allergic vasculitis Reaction time: from 24 h In new sensitization under treatment Typical sensitization latency: 5-10 days in type I-IV, rarely longer: weeks to months, e. g., in SJS/TEN, DRESS, autoimmune diseases (e. g., lupus erythematosus) Atopic disease, food allergy/intolerance -Predisposing diseases [e.</s><s>g., bronchial asthma, nasal polyps, chronic urticaria, mastocytosis, infections such as human immunode ciency virus (HIV), Epstein-Barr virus (EBV)] -Other relevant previous or current diseases (e. g., somatoform disorders or mental illness) -Noxious agents: nicotine, alcohol, illicit drugs -Current medication E. Chronology of the ADR: -Timing in relation to drug use -First onset -Course and resolution erapeutic measures and response in terms of the clinical course F. Diagnosis and pathophysiological classi cation of the clinical reaction taking into account (see Tab. 1): -Morphology and symptoms -Time course Note: In the case of multiple reactions information is required for each individual reaction.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1 :</head><label>1</label><figDesc><div><p><s>Fig. 1: Diagnostic algorithm for suspected drug hypersensitivity a In individual cases, e. g., aspirin-exacerbated respiratory disease, a diagnosis can be made on the basis of an unequivocal patient history.</s><s>Pharmacological side effects or irrelevant symptoms do not require a diagnostic work-up.b</s><s>Diagnostic work-up can be dispensed with if the suspected drug is unlikely to be needed for treatment purposes in the future (e. g., sulfonamide antibiotics).</s><s>c Validated skin and/or laboratory tests are available for only a small number of drug groups; these include β-lactam antibiotics, heparins, radiocontrast media, muscle relaxants, and platinum compounds.</s><s>For many drugs, no valid tests are available and/or their sensitivity is low.</s><s>For this reason, skin and laboratory tests always need to be assessed in conjunction with all available data.</s><s>Controlled provocation testing is often required to establish or exclude a diagnosis.</s><s>d Provocation test with the suspected drug, taking contraindications into consideration.</s><s>In some situations, provocation tests with alternative drugs are helpful, e. g., COX-II inhibitors in aspirin-exacerbated respiratory disease</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>-</head><label></label><figDesc><div><p><s>Su cient interval since drug reaction and allergy medication.</s><s>-In-patient medical supervision in the case of provocation tests with the potential to trigger systemic reactions.</s><s>-Appropriate medical supervision for the entire duration of the provocation test, as well as a safety interval determined by the reaction type, following administration of the nal test dose.</s><s>-Consideration of the pharmacological e ects of drugs (e. g., narcotics, antidiabetic agents, neuroleptic agents, heparins) and their respective maximum doses, as well as possible altered pharmacokinetics in the patient (e.g., impaired liver or kidney function).</s><s>-In the case of systemic administration, drugs should be administered in incremental doses (e.g., [1%] -10 % -50 % -100 % or [1%] -3 % -10 % -30 % -100 % of the usual single dose, possibly up Tab.</s><s>5: A selection of tests commercially available from a manufacturer to determine speci c immunoglobulin-E (sIgE) anti-drug antibodies in serum*</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Tab. 2: Time interval, symptoms, and pathomechanism: the three levels of classi cation for drug hypersensitivity reactions</head><label></label><figDesc></figDesc><table><row><cell>Type A ("augmented": pharmacological/toxic drug reaction)</cell><cell></cell></row><row><cell cols="2">Disease manifestations due to predictable, dose-dependent pharmacological/toxic</cell></row><row><cell cols="2">effects typical for a drug at the recommended dose (e.g., sedative effect of older anti-</cell></row><row><cell cols="2">histamines, hair loss caused by cytostatics) or at higher doses (intoxication)</cell></row><row><cell>Type B ("bizarre": hypersensitivity reactions)</cell><cell></cell></row><row><cell cols="2">Individual, unpredictable clinical reaction to a drug, i.e., disease manifestations occur in</cell></row><row><cell cols="2">specifically predisposed patients; a distinction is made between two forms:</cell></row><row><cell>Drug allergy:</cell><cell></cell></row><row><cell cols="2">Hypersensitivity is based on an immunological reaction (types I-IV according to Coombs</cell></row><row><cell>and Gell)</cell><cell></cell></row><row><cell>Non-immunological drug hypersensitivity:</cell><cell></cell></row><row><cell cols="2">An immunological (allergic) reaction mechanism cannot be detected. This form of</cell></row><row><cell>reaction was formerly further subdivided into:</cell><cell></cell></row><row><cell cols="2">-Drug intolerance: typical symptoms of the pharmacological effect (toxicity) develop already at low doses, which are usually tolerated</cell></row><row><cell cols="2">-Drug idiosyncrasy: Symptoms differ from the pharmacological effect of the substance. Reactions involving symptoms that correspond to allergic disease</cell></row><row><cell>were also referred to as pseudo-allergies</cell><cell></cell></row><row><cell>tract, cardiovascular reactions, gastrointestinal</cell><cell>-Patient whereabouts and activities</cell></row><row><cell>reactions, liver, kidneys</cell><cell>-Cofactors for allergic reactions: stress, exertion,</cell></row><row><cell>-Precise description of clinical and morphological</cell><cell>food intake, alcohol consumption, ultraviolet</cell></row><row><cell>ndings (particularly in the case of skin manifes-</cell><cell>(UV) exposure</cell></row><row><cell>tations/mucosal reactions), in addition to photo-</cell><cell>C. Documentation of drugs used in temporal rela-</cell></row><row><cell>documentation</cell><cell>tion to the reaction:</cell></row><row><cell>-General symptoms: fever, fatigue</cell><cell>-Indication for drug use</cell></row><row><cell>-Course of the reaction (reaction onset in temporal</cell><cell>-Trade name (ideally with batch no.; is a sample</cell></row><row><cell>relation to drug use, duration of the reaction,</cell><cell>available?)</cell></row><row><cell>morphological change of the reaction)</cell><cell>-Mode of application</cell></row><row><cell>-Laboratory ndings (e. g., changes in blood count,</cell><cell>-Ingredients (active substance, excipients)</cell></row><row><cell>such as eosinophilia, neutrophilia, thrombocyto-</cell><cell>-Duration of use</cell></row><row><cell>penia; liver and kidney function; serum tryptase</cell><cell>-Dosage</cell></row><row><cell>level)</cell><cell>-Tolerance in the case of earlier or repeated use</cell></row><row><cell>-Where appropriate, histological ndings (espe-</cell><cell>D. General patient history and clinical ndings:</cell></row><row><cell>cially in skin manifestations)</cell><cell>-Basic data (sex, age, profession)</cell></row><row><cell>B. Additional factors associated with the reaction:</cell><cell>-Known hypersensitivity reactions (allergy passport)</cell></row><row><cell>-Acute diseases at the time of the reaction (e. g.,</cell><cell>-Similar reactions in the absence of drug use (e. g.,</cell></row><row><cell>inter current infections)</cell><cell>natural latex allergy)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Validated skin and/or laboratory tests are available for only a small number of drug groups; these include β-lactam antibiotics, heparins, radiocontrast media, muscle relaxants, and platinum compounds.</s><s>For many drugs, no valid tests are available and/or their sensitivity is low.</s><s>For this reason, skin and laboratory tests always need to be assessed in conjunction with all available data.</s><s>Controlled provocation testing is often required to establish or exclude a diagnosis.</s><s>d Provocation test with the suspected drug, taking contraindications into consideration.</s><s>In some situations, provocation tests with alternative drugs are helpful, e. g., COX-II inhibitors in aspirin-exacerbated respiratory disease</s></p></div></figDesc><table><row><cell cols="4">Suspected drug hypersensitivity</cell><cell></cell></row><row><cell>Clinically</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>unequivocal a</cell><cell>Assessment</cell><cell></cell><cell>Unlikely</cell><cell>No allergy</cell></row><row><cell></cell><cell cols="2">of history and</cell><cell></cell><cell>diagnostic</cell></row><row><cell></cell><cell>symptoms</cell><cell></cell><cell></cell><cell>work-up</cell></row><row><cell></cell><cell cols="3">Possible or likely b</cell><cell></cell></row><row><cell></cell><cell cols="2">Are validated</cell><cell>No</cell><cell></cell></row><row><cell></cell><cell cols="2">tests available? c</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>Skin tests</cell><cell></cell><cell>Negative</cell><cell>Is provocation</cell><cell>No</cell></row><row><cell></cell><cell cols="2">Laboratory tests c</cell><cell></cell><cell>possible?</cell></row><row><cell cols="2">Positive</cell><cell cols="2">Provocation test</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Negative</cell><cell></cell></row><row><cell>Confirmed drug hypersensitivity</cell><cell></cell><cell></cell><cell></cell><cell cols="2">Possible drug hypersensitivity</cell></row><row><cell>• Documentation (allergy passport)</cell><cell></cell><cell></cell><cell></cell><cell cols="2">• Documentation (allergy passport)</cell></row><row><cell>• Avoidance</cell><cell></cell><cell></cell><cell></cell><cell>• Avoidance</cell></row><row><cell>• Desensitization as appropriate</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>b Diagnostic work-up can be dispensed with if the suspected drug is unlikely to be needed for treatment purposes in the future (e. g., sulfonamide antibiotics).</s><s>c d Drug hypersensitivity ruled out essential that non-irritant test concentrations are used.</s><s>However, for many drugs optimal test concentrations are not known.</s><s>Recommendations on a number of drugs have been developed recently;</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>Skin test reactions can occur at other points in time, sometimes also a er more than 1 week.</s><s>Patients need to be informed that, in such cases, they should seek immediate medical advice from the treating physician.</s></p></div></figDesc><table><row><cell></cell><cell>Test procedure</cell></row><row><cell></cell><cell>-Su cient interval since drug reaction and allergy</cell></row><row><cell></cell><cell>medication.</cell></row><row><cell></cell><cell>-In the case of tests at risk for eliciting a systemic</cell></row><row><cell></cell><cell>reaction, adequate medical supervision of the pa-</cell></row><row><cell></cell><cell>tient over a su cient time period; where appro-</cell></row><row><cell></cell><cell>priate, threshold testing with diluted solutions.</cell></row><row><cell></cell><cell>-Sequence of test procedures: prick test prior to</cell></row><row><cell></cell><cell>intradermal test; patch test (where appropriate,</cell></row><row><cell></cell><cell>open prior to closed prior to tape-stripping patch</cell></row><row><cell></cell><cell>test); in the case of suspected photo-induced re-</cell></row><row><cell></cell><cell>actions, additional tests in combination with UV</cell></row><row><cell></cell><cell>light (e. g., photo-patch test).</cell></row><row><cell></cell><cell>-Painful intradermal tests should be used sparingly</cell></row><row><cell></cell><cell>in children, especially infants and young children.</cell></row><row><cell></cell><cell>-Timing of tests (simultaneous or consecutive test-</cell></row><row><cell></cell><cell>ing of di erent substances or substance concentra-</cell></row><row><cell></cell><cell>tions) is selected according to the suspected patho-</cell></row><row><cell></cell><cell>mechanism, the severity of the reaction, and the</cell></row><row><cell></cell><cell>risks associated with the chosen skin test method.</cell></row><row><cell></cell><cell>Prick and intradermal test reactions are typically</cell></row><row><cell></cell><cell>read a er 15-20 min, patch tests a er 24-48 h and</cell></row><row><cell></cell><cell>72 h. In the case of drug eruptions, late readings af-</cell></row><row><cell></cell><cell>ter 24 and 48 h (or 48 and 72 h) should be per-</cell></row><row><cell></cell><cell>formed for prick and intradermal tests (e. g., when</cell></row><row><cell></cell><cell>investigating amoxicillin eruptions). In the case of</cell></row><row><cell>Test material</cell><cell>anaphylactic symptoms and high-risk of systemic</cell></row><row><cell>-Medicinal preparations used, active substances,</cell><cell>test reactions, it is possible to perform an open</cell></row><row><cell>and excipients</cell><cell>patch test with an early reading a er 20-30 min</cell></row><row><cell>-Positive and negative controls depending on the</cell><cell>(e. g., when investigating anaphylaxis following</cell></row><row><cell>test method</cell><cell>topical application of bacitracin). Additional read-</cell></row><row><cell>-Appropriate test concentrations to avoid irrita-</cell><cell></cell></row><row><cell>tive/toxic or pharmacological reactions (e. g., to</cell><cell></cell></row><row><cell>morphine derivatives, gyrase inhibitors) or false-</cell><cell></cell></row><row><cell>negative test failure (where appropriate, threshold</cell><cell></cell></row><row><cell>tests)</cell><cell></cell></row><row><cell>-Substance should be prepared in a manner suited</cell><cell></cell></row><row><cell>to skin testing</cell><cell></cell></row></table><note><p><s>ings can be helpful, e. g., patch test readings a er 7 days in the case of glucocorticoid allergy.</s><s>Note:</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Non-irritant skin test concentrations of frequently tested drugs [14]</head><label></label><figDesc></figDesc><table><row><cell>Interpreting test results</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Hypersensitivity reaction -Readings should be made according to the recom-Time interval Tab. 4: Drug or drug class Prick test mended criteria for the test procedure used, and unusual morphological features documented.</cell><cell>Intradermal test h</cell><cell>Patch test</cell></row><row><cell cols="3">Urticaria, asthma, anaphylaxis β-Lactam antibiotics -In the case of reactions to medicinal preparations, typically within 1 h, in rare cases up to 12 h after exposure Maculopapular drug eruption 4-14 Days after start of use a Penicilloyl poly-L-lysine 5×10 -5 mM further testing of the individual ingredients, 5×10 -5 mM where available, should be performed.</cell><cell>NA</cell></row><row><cell cols="2">AGEP SJS/TEN Minor determinant mixture -In the case of skin reactions, a nonspeci c reac-1-12 Days after start of use b 2×10 -2 mM tion should be excluded where possible. 4-28 Days after start of use c Benzylpenicillin 10,000 UI/ml -Only when non-irritant test concentrations are</cell><cell>2×10 -2 mM 10,000 UI/ml</cell><cell>NA 5 %</cell></row><row><cell cols="3">DRESS Amoxicillin used is it sometimes possible to de nitively dia-2-8 Weeks after start of use 20 mg/ml gnose an individual allergy (e. g., β-lactam anti-AGEP, acute generalized exanthematous pustulosis; SJS, Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; DRESS, drug reaction with 20 mg/ml eosinophilia and systemic symptoms. Ampicillin 20 mg/ml 20 mg/ml biotic or heparin allergy) on the basis of "positive"</cell><cell>5 % 5 %</cell></row><row><cell cols="4">a Time interval in repeat reactions typically shorter compared with the first reaction. In maculopapular drug eruptions, reaction typically seen after Cephalosporins 2 mg/ml 2 mg/ml 5 % skin tests combined with patient history. In all 1-4 days, typical time interval for repeat reactions has not been investigated in AGEP, SJS, TEN, and DRESS; b mostly 1-2 days with antibiotics, often 7-12 days with other medications; c sometimes longer with allopurinol other cases, additional investigations (in vitro Anticoagulants tests, provocation tests) are required.</cell></row><row><cell>Heparins a</cell><cell>undiluted h</cell><cell>1/10 diluted</cell><cell>undiluted h</cell></row><row><cell>Heparinoids b</cell><cell>undiluted h</cell><cell>1/10 diluted</cell><cell>undiluted h</cell></row><row><cell>Platinum salts</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Carboplatin</cell><cell>10 mg/ml</cell><cell>1 mg/ml</cell><cell>NA</cell></row><row><cell>Oxaliplatin</cell><cell>1 mg/ml</cell><cell>0.1 mg/ml</cell><cell>NA</cell></row><row><cell>Cisplatin</cell><cell>1 mg/ml</cell><cell>0.1 mg/ml</cell><cell>NA</cell></row><row><cell>NSAIDs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pyrazolones c</cell><cell>Suspension i</cell><cell>0,1-1 mg/ml</cell><cell>10 %</cell></row><row><cell>Coxibs d</cell><cell>Suspension i</cell><cell>NA</cell><cell>10 %</cell></row><row><cell>Other NSAID e</cell><cell>Suspension i</cell><cell>0.1-1 mg/ml</cell><cell>10 %</cell></row><row><cell>Biologicals</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Adalimumab</cell><cell>50 mg/ml</cell><cell>50 mg/ml</cell><cell>undiluted h</cell></row><row><cell>Etanercept</cell><cell>25 mg/ml</cell><cell>5 mg/ml</cell><cell>NA</cell></row><row><cell>Infliximab</cell><cell>10 mg/ml</cell><cell>10 mg/ml</cell><cell>NA</cell></row><row><cell>Omalizumab</cell><cell>1.25 μg/ml</cell><cell>1.25 μg/ml</cell><cell>NA</cell></row><row><cell>Others</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Local anesthetics</cell><cell>Undiluted h</cell><cell>1/10 diluted</cell><cell>undiluted h</cell></row><row><cell>Iodinated contrast media</cell><cell>Undiluted h</cell><cell>1/10 diluted</cell><cell>undiluted h</cell></row><row><cell>Gadolinium chelates</cell><cell>Undiluted h</cell><cell>1/10 diluted</cell><cell>NA</cell></row><row><cell>Patent blue</cell><cell>Undiluted</cell><cell>1/10 diluted</cell><cell>NA</cell></row><row><cell>Methylene blue</cell><cell>Undiluted</cell><cell>1/100 diluted</cell><cell>NA</cell></row><row><cell>Fluorescein</cell><cell>Undiluted h</cell><cell>1/10 diluted</cell><cell>undiluted h</cell></row><row><cell>Proton pump inhibitors f</cell><cell>Undiluted h</cell><cell>40 mg/ml</cell><cell>10 %</cell></row><row><cell>Anticonvulsants g</cell><cell>NA</cell><cell>NA</cell><cell>10 %</cell></row><row><cell>Chlorhexidine digluconate</cell><cell>5 mg/ml</cell><cell>0.002 mg/ml</cell><cell>1 %</cell></row></table><note><p><s>NA, not applicable or no recommended concentration; NSAID, non-steroidal anti-inflammatory drugs a Heparins: unfractionated heparin, nadroparin, dalteparin, enoxaparin; testing contraindicated in heparin-induced thrombocytopenia; b heparinoids: danaparoid, fondaparinux; c pyrazolones: metamizole, propyphenazone, aminopyrine, phenazone, phenylbutazone; d coxibs: celecoxib, etoricoxib, valdecoxib; e other NSAIDs: e. g., aspirin, ibuprofen, naproxen, indomethacin, diclofenac, fenoprofen, meloxicam, mefenamic acid, nimesulide; f no intravenous solution available for intradermal testing with lansoprazole and rabeprazole, onlyfor prick testing; g test initially with 1 % in the case of severe reactions; h use of the commercially available solution for intravenous infusion or subcutaneous injection; i tablet is ground to a powder and a suspension prepared using physiological saline solution</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head></head><label></label><figDesc><div><p><s>It is important to ensure that test methods have been validated when determining sIgE to drugs.</s><s>CE certification requires at least five, the US Food and Drug Administration (FDA) at least 30 positive patient sera, as well as studies on stability and reproducibility.</s><s>Where these criteria have not been fulfilled, test reagents are offered for research purposes where appropriate.</s><s>Particular attention should be paid here to the quality of the available literature.</s></p></div></figDesc><table><row><cell>to the daily dose or the dose given in the patient</cell></row><row><cell>history) at an interval determined according to</cell></row><row><cell>the suspected reaction mechanism (30 min-2</cell></row><row><cell>days), possibly with the additional administration</cell></row><row><cell>at therapeutic daily doses for several days (e. g.,</cell></row><row><cell>drug eruptionsexanthems). In the case of erup-</cell></row><row><cell>tions eczematous reactions to external agents, a</cell></row><row><cell>non-fractionated application test is possible.</cell></row><row><cell>-Co-exposure to the co-stimulus when a reaction</cell></row><row><cell>to a combination of triggers is suspected (e. g., ex-</cell></row><row><cell>ercise-induced anaphylaxis).</cell></row><row><cell>-Single-blind (double-blind) tests with appropriate</cell></row><row><cell>placebo controls.</cell></row><row><cell>-e results of non-blind provocation tests are of</cell></row><row><cell>diagnostic use only in the case of negative results</cell></row><row><cell>or unequivocal clinical symptoms.</cell></row><row><cell>-Placebo controls must be performed in precisely</cell></row><row><cell>the same manner as verum controls in multiple</cell></row><row><cell>dosages (for examples, see Tab. 5).</cell></row><row><cell>-Management of hazardous test reactions.</cell></row><row><cell>Note: It is essential that drugs and medical equip-</cell></row><row><cell>ment required for emergency treatment is available</cell></row><row><cell>and that personnel are experienced in the manage-</cell></row><row><cell>ment of acute emergencies.</cell></row><row><cell>-Su cient interval between test reaction and sub-</cell></row><row><cell>sequent tests (e. g., refractory phase).</cell></row><row><cell>-Patients must be informed on how to react if a</cell></row><row><cell>reaction occurs a er the period of medical super-</cell></row><row><cell>vision.</cell></row></table><note><p><s>*Determination of sIgE against substances for which no IgE-mediated allergic reactions have been described as yet should not be performed in routine diagnostics.</s><s>a CE-certified and FDA-registered b CE-certified; c CE certification in preparation; d for research purposes only; e α-Gal, this is an IgE-reactive sugar epitope held responsible for anaphylactic reactions to cetuximab and infusion solutions containing gelatin</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Allergo J Int 2015; 24: 94-105</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>that future tolerance of alternative substances/preparations cannot be guaranteed with 100% certainty.</s><s>Information on possible drug prophylaxis against hypersensitivity reactions (e. g., premedication when using radiocontrast media or for surgical procedures under general anesthesia) as well as on tolerance induction should also be in cluded.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Con ict of interests</head><p><s>The information on potential con icts of interest have been reviewed by a steering-group which did not nd any con icts of interest which may a ect the authors' independency in the process of the development of this guideline.</s><s>The authors' disclosures are available in a table (together with the working-report on this guideline) on the AWMF-page of the S2k-Guideline for the diagnosis of drug hypersensitivity reactions via www.awmf.org/</s><s>leitlinien/detail/ll/061-021.html.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cite this as</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">International Consensus (ICON) on Drug Allergy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Demoly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Adkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="420" to="437" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Allergologische Diagnostik von Überemp ndlichkeitsreaktionen auf Arzneimittel</title>
		<author>
			<persName><forename type="first">B</forename><surname>Przybilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergo J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="90" to="94" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Drug hypersensitivity reactions: inconsistency in the use of the classi cation of immediate and nonimmediate reactions</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bircher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Scherer Hofmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="265" to="266" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The drug ambassador project: the diversity of diagnostic procedures for drug allergy around</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Demoly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europe. J World Allergy Org</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Blanca-Lopez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="242" to="248" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Anaphylaxis to radiographic contrast media</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="326" to="331" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clinical value of radiocontrast media skin tests as a prescreening and diagnostic tool in hypersensitivity reactions</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Jo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="999" to="1003" />
			<date type="published" when="1999">2013. 2005. 1999</date>
		</imprint>
	</monogr>
	<note>Allergy</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Hauttests zur Diagnostik von allergischen Soforttypreaktionen</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergo J</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="402" to="415" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">General considerations for skin test procedures in the diagnosis of drug hypersensitivity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blanca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="45" to="51" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Anaphylaxis during anesthesia in France: an 8-year national survey</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Mertes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trechot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="366" to="373" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Dilemmas of allergy diagnosis in perioperative anaphylaxis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1265" to="1266" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Skin test concentrations for systemically administered drugs -an ENDA/ EAACI Drug Allergy Interest Group position paper</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Garvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="702" to="712" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Ceftriaxone intradermal test-related fatal anaphylactic shock: a medico-legal nightmare</title>
		<author>
			<persName><forename type="first">I</forename><surname>Riezzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="130" to="131" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Akuttherapie und Management der Anaphylaxie</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Biedermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergo J Int</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="36" to="52" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology</title>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1026" to="1045" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">In-vitro-Allergiediagnostik. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie</title>
		<author>
			<persName><forename type="first">H</forename><surname>Renz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bufe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergo J</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="492" to="506" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Epidemiologie, Klinik, Auslöser und Management</title>
		<author>
			<persName><forename type="first">K</forename><surname>Brockow</surname></persName>
		</author>
		<author>
			<persName><surname>Arzneimittelreaktionen</surname></persName>
		</author>
		<author>
			<persName><surname>Soforttyp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hautarzt</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="409" to="414" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Analyzing histamine release by ow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Ebo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Bridts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mertens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="30" to="38" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">In vitro diagnosis of T cell-mediated drug allergy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Porebski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gschwend-Zawodniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Pichler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="461" to="470" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations</title>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bircher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="854" to="863" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Classi cation and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-in ammatory drugs</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Kowalski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bavbek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1219" to="1232" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Evaluating the negative predictive value of provocation tests with nonsteroidal anti-in ammatory drugs</title>
		<author>
			<persName><forename type="first">C</forename><surname>Defrance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Demoly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1410" to="1414" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Determining the negative predictive value of provocation tests with betalactams</title>
		<author>
			<persName><forename type="first">P</forename><surname>Demoly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Botelho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="327" to="332" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Classi cation of allergic reactions responsible for clinical hypersensitivity and disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Coombs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Gell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Aspects of Immunology</title>
		<editor>Gell RR</editor>
		<imprint>
			<biblScope unit="page" from="575" to="596" />
			<date type="published" when="1968">1968</date>
			<publisher>Oxford University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Allergo J Int</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="94" to="105" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
